Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 21, 1999

View Archived Issues

Roche and Genentech relationship unaffected by public offering; Genentech provides Q3 update

Licensing opportunity from NIH: aspartic HIV protease inhibitors

Atlantic reports analgesic effects of CT-3 in mouse model

Teva announces possible acquisition of Novopharm

Orphan Medical completes licensing agreement with Pierre Fabre

Vasogen cleared to proceed with psoriasis clinical trial

Expanded agreement between Vertex and HMR receives Hart-Scott-Rodino clearance

Centocor submits sBLA to FDA for Remicade as treatment of rheumatoid arthritis

StressGen completes clinical trial with lead product during third quarter

Roche patents new compounds with MDM2-antagonist activity useful for treatment of tumors

Galderma describes new apoptosis-inducing antitumor agents

Novel prostaglandin analogues useful for bone disorders, glaucoma

Retinoid receptor-active compounds from Galderma for skin disorders

Neuroprotective fullerene derivatives designed by Aventis R&T

EASD highlights: novel aldose reductase inhibitor effective in model of diabetic neuropathy

Wilex and Ludwig Institute collaborate on clinical development of G250

Sonus's lead ultrasound contrast agent moves closer to commercialization

Chemosensitizing agent from Procept enters phase II for multiple myeloma

Phase II clinical trials initiated for humanized anti-CD3 antibody developed at PDL

First prescription drug approved in U.K. for severe PMS

Proof-of-concept trial begins for Vivus's oral PE compounds

The antidementia drug donepezil may also be beneficial in Lewy body dementia

Neuroprotective effects demonstrated for mglu receptor agonists in vitro and in vivo

Increasing NO levels in blood as novel strategy for sickle cell disease

Xyrem headed for NDA submission in a year

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.